Cytogenetics in the management of hematologic neoplasms with germline predisposition: guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH)

Curr Res Transl Med. 2023 Oct-Dec;71(4):103416. doi: 10.1016/j.retram.2023.103416. Epub 2023 Oct 21.

Abstract

The number of predisposing genes is continuously growing with the widespread availability of DNA sequencing, increasing the prevalence of hematologic malignancies with germline predisposition. Cytogenetic analyses provide an effective approach for the recognition of these malignancies with germline predisposition, which is critical for proper diagnosis, optimal treatment and genetic counseling. Based on the World Health Organization and the international consensus classifications as well as the European LeukemiaNet recommendations, this review first presents an advanced classification of neoplasms with germline predisposition focused on the acquired cytogenetic alterations during leukemogenesis. The various genetic rescue mechanisms and the progression to transformation are then explained. The review also outlines the specific constitutional and somatic cytogenetic aberrations indicative of germline predisposition disorders in B-acute lymphoblastic leukemia (ALL), T-ALL, bone marrow failure syndrome and myeloid neoplasms. An emphasis is made on monosomy 7 in the predisposition field, its frequency and diagnosis impact as well as its various circumstances of occurrence. Lastly, we propose cytogenetic technical recommendations and guidelines for clinical reporting of these specific aberrations.

Keywords: Cytogenetic abnormalities; Genetic rescue; Germline predisposition; Hematologic neoplasms; Monosomy 7.

Publication types

  • Review
  • Practice Guideline

MeSH terms

  • Cytogenetic Analysis
  • Disease Susceptibility
  • Germ Cells
  • Hematologic Neoplasms* / diagnosis
  • Hematologic Neoplasms* / epidemiology
  • Hematologic Neoplasms* / genetics
  • Hematology*
  • Humans
  • Societies, Medical